Release Date: December 23, 2025
Expiration Date: December 23, 2026
Activity Overview
Schizophrenia represents a major psychiatric disorder characterized by symptoms that frequently compromise daily functioning and diminish overall quality of life. While effective management can lead to improved patient outcomes, many individuals continue to struggle with persistent or residual symptoms, medication adherence challenges, and adverse drug reactions. In particular, poor adherence to oral antipsychotic treatment increases the likelihood of symptom recurrence and psychiatric hospitalization. To address these challenges, long-acting injectable (LAI) antipsychotic formulations have been developed that offer advantages, such as eliminating the need for daily medication administration, maintaining more stable drug levels in the bloodstream, and facilitating consistent clinical oversight.
This educational program brings together clinical experts to examine how long-acting injectable antipsychotics can be effectively utilized in schizophrenia treatment, emphasizing their therapeutic benefits and safety profiles while exploring optimal strategies for incorporating these medications into personalized patient care approaches.
This educational activity is an archive of the live virtual symposium held at the Southern Florida Psychiatry conference on November 21, 2025.
Target Audience
This educational activity is directed toward psychiatrists who treat patients with a range of psychiatric disorders. Psychiatric nurse practitioners, psychiatric nurses, and other health care professionals interested in the treatment of patients with psychiatric disorders are invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better
prepared to:
- Review relevant clinical characteristics of long-acting injectable agents for schizophrenia
- Integrate long-acting injectable medications into individualized management plans for patients with schizophrenia
Patricia Junquera, MD
Chair, Associate Professor
Department of Psychiatry and Behavioral Health
FIU Herbert Wertheim College of Medicine
Miami, FL
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Teva
Maria Collado, MD
Assistant Professor, Herbert Wertheim College of Medicine
Florida International University
Clinical Director, Adult Crisis Stabilization Unit
Citrus Health Network, Inc.
Miami, FL
Disclosures: Maria Collado, MD, has no relevant financial relationships with ineligible companies.
Erin C. Crown, MHSPAS, PA-C, Psych-CAQ
Managing Member, Oasis LifeCare, LLC
Owner, Future Options Research
State College, PA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AbbVie, Axsome Therapeutics, Bristol Myers Squibb, Intra-Cellular Therapies, Johnson & Johnson, Lundbeck, Neurocrine Biosciences, Otsuka America Pharmaceutical
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here